Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSPW3N)

Drug Name
ACH-2928 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMSPW3N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Hepatitis C virus Non-structural 5A (HCV NS5A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Daclatasvir DMSFK9V Hepatitis C virus infection 1E51.1 Approved [3]
Glecaprevir; pibrentasvir DMF6Z5T Hepatitis C virus infection 1E51.1 Approved [4]
ABT-267 DMNQ869 Hepatitis C virus infection 1E51.1 Phase 3 [5]
MK-8742 DMK301H Hepatitis C virus infection 1E51.1 Phase 3 [6]
Ravidasvir DM1LFUN Hepatitis C 1E51 Phase 2/3 [7]
GS-5885 DMSL3DX Hepatitis C virus infection 1E51.1 Phase 2 [8]
PPI-668 DM4EHVB Hepatitis C virus infection 1E51.1 Phase 2 [9]
ACH-3102 DM0RPY5 Hepatitis C virus infection 1E51.1 Phase 2 [9]
AZD-2836 DMT2FAP Hepatitis C virus infection 1E51.1 Phase 1/2 [10]
BMS-824383 DMPQ5XC Hepatitis C virus infection 1E51.1 Phase 1 [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis C virus Non-structural 5A (HCV NS5A) TTCJ2X8 POLG_HCV1 Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032623)
2 Company report (Achillion)
3 2011 Pipeline of Bristol-Myers Squibb.
4 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
5 Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57.
6 Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013 Dec;8(12):1930-40.
7 Clinical pipeline report, company report or official report of Presidio Pharmaceuticals.
8 Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57(5):2033-46.
9 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
10 TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future. 2011 September; 36(9): 691-711.